CheckMate 817 is phase IV study evaluating the safety profile of combined nivolumab–ipilimumab treatment in individuals who have not received prior systemic treatment for stage IV or recurrent non-small-cell lung cancer. It is a multicohort study that includes certain special populations, such as patients with poor functional status and those with high tumor mutational burden.
Fabrice Barlesi discusses the CheckMate 817 trial and whether first-line nivolumab–ipilimumab is a feasible option for certain subgroups of advanced non-small-cell lung cancer patients, such as those with poor functional status (3:32):
Results were presented at WCLC 2019:
Title: CheckMate 817: First-line nivolumab + ipilimumab in patients with ECOG PS 2 and other special populations with advanced NSCLC
Presenter: Fabrice Barlesi, Aix Marseille University, France
Sunday, September 8: 15:25–15:35 (Abstract OA04.02)